Natera, Inc.(NTRA) - Stock detail

Natera, Inc.

US
NTRA
Natera, Inc.(Listing date: 07/02/2015)

Natera, Inc. was incorporated in Delaware in January 2007. The company is a diagnostic company with proprietary molecular and bioinformatics technologies that it is applying to transform disease management worldwide. The company's cell-free DNA (cfDNA) technology combines novel molecular analytical methods that can reliably measure many informative regions across the entire genome from samples as small as a single cell, as well as statistical algorithms that incorporate data provided by the broader scientific community to identify genetic variations covering a wide range of serious diseases with high precision and high coverage. The company's goal is to make personalized genetic testing and diagnosis part of the standard of care for protecting health and inform earlier and more targeted interventions to help achieve longer, healthier lives.

AI Trading DecisionBuy
Generated at:2026-04-24 17:45:46
Analysis based on company fundamentals (FY2025 revenue, margins), technical indicators (price, support/resistance levels, ADX, ATR), valuation metrics (PS ratio), and market context. Data includes current price as of 2026-04-24, historical price levels (April low/high), and moving averages (20-day, 60-day SMA).
Summary

This report recommends a BUY on Natera, Inc. (NTRA) with a 6-month target price of $280.00, representing a +37.4% expected increase from the current price of $203.75. A stop-loss price is set at $182.00, below the critical $184 support level. The confidence level in this decision is 0.72 (High), and the risk score is 0.68 (Moderate-High), reflecting the stock's inherent volatility mitigated by strong company-specific catalysts and defined risk parameters.

Operation strategy
  • Entry Zone: $200-$205 (current consolidation range)
  • Stop-Loss: $182 (below critical $184 support)
  • Position Sizing: Moderate allocation due to high volatility
  • Add-on Trigger: Break above $210 with volume expansion

Core Support

Reasoning summary
  • Exceptional Growth Trajectory: Natera achieved 36% revenue growth on a $2.31B base in FY2025, with accelerating absolute dollar growth.
  • Margin Expansion Signals Profitability Path: Gross margin improved to 64.75% (+450+ bps YoY), demonstrating pricing power and operational leverage.
  • Diversified Growth Engines: Signatera is transitioning to standard of care in oncology MRD testing, and the Zenith launch expands into rare genetic diseases with a billion-dollar TAM.
  • Strengthening Competitive Moat: Recent patent victory against ArcherDx/Invitae strengthens IP protection, and extensive clinical data creates a significant barrier to entry.
  • Consolidation, Not Breakdown: Current price sits at the lower end of a reasonable PS-based range ($192-$288), with an ADX of 10.28 indicating trendless consolidation.
  • Support Levels Provide Risk Management: Immediate support at $200 and $202.79 (20-day SMA), with critical support at $184 (April low).
  • Valuation Gap: Current PS ratio of 12.6x is reasonable for a company with 35%+ growth, 65%+ gross margins, and a visible path to profitability.
  • Risk Factors Mitigated: Strong balance sheet (current ratio 3.39) provides runway without dilution risk, mitigating concerns over the profitability timeline.